Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age

Cancer Research

Volumn 72, Issue 8, 2012, Pages 2028-2035

  Li, Christopher I ^a   Beaber, Elisabeth F ^a   Tang, Mei Tzu Chen ^a   Porter, Peggy L ^a   Daling, Janet R ^a   Malone, Kathleen E ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; HORMONE RECEPTOR; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; STRUCTURED INTERVIEW; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; RISK FACTORS; YOUNG ADULT;

EID: 84860129586     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-4064     Document Type: Article

References (22)

1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53. (Pubitemid 37430077)
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
3. Frost JJ, Jones RK, Woog V, Singh S, Darroch JE. Teenage sexual and reproductive behavior in developed countries: Country report for the United States. Occasional Report No. 8. New York, NY: The Alan Guttmacher Institute; 2001.
4. Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 1987;79:1247-54. (Pubitemid 18036729)
5. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet 1991;338:833-8.
6. Paul C, Skegg DC, Spears GF. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. BMJ 1989;299:759-62. (Pubitemid 19237024)
7. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000;151:396-403. (Pubitemid 30463617)
8. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc 1978;73:40.
9. Voigt LF, Davis S, Heuser L. Random digit dialing: the potential effect on sample characteristics of the conversion of nonresidential telephone numbers. Am J Epidemiol 1992;136:1393-9. (Pubitemid 23046424)
10. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996;41:381-90.
11. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 1977;44:32-8. (Pubitemid 8030779)
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
14. Begg CB, Gray R. Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika 1984;71:11-8.
15. Dolle JM, Daling JR,White E, Brinton LA, DoodyDR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-66.
16. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502. (Pubitemid 43854964)
17. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37:1217-26. (Pubitemid 44286991)
18. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-70.
19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
20. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 2008;112:737-47. (Pubitemid 351240567)
21. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008;14:456-63.
22. Voigt LF, Schwartz SM, Doody DR, Lee SC, Li CI. Feasibility of including cellular telephone numbers in random digit dialing for epidemiologic case-control studies. Am J Epidemiol 2011;173:118-26.